Feedback
Settings

Settings

Goto Application

280,389 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,039
1.WO/2025/252112DISACCHARIDE COMPOUND, ANTIBODY-DRUG CONJUGATE CONTAINING DISACCHARIDE COMPOUND, AND USE THEREOF
WO - 11.12.2025
Int.Class C07H 15/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
04attached to an oxygen atom of a saccharide radical
08Polyoxyalkylene derivatives
 Appl.No PCT/CN2025/099004 Applicant HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. Inventor LI, Zhen
Provided are a disaccharide compound represented by formula I, an antibody-drug conjugate containing the disaccharide compound, and the use thereof as an anti-tumor drug, etc.
2.WO/2025/252741NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
WO - 11.12.2025
Int.Class C07H 15/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
26Acyclic or carbocyclic radicals, substituted by hetero rings
 Appl.No PCT/EP2025/065355 Applicant GALECTO BIOTECH AB Inventor PETERSON, Kristoffer
The present invention relates to a high affinity galectin-3 inhibitor alpha-D-galactopyranose derivative of formula (I), a pharmaceutical salt or solvate thereof, for use in treatment of inflammation.
3.WO/2025/255246COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
WO - 11.12.2025
Int.Class C07H 19/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
 Appl.No PCT/US2025/032288 Applicant ROME THERAPEUTICS, INC. Inventor CHOBANIAN, Harry R.
Compounds, pharmaceutical compositions, and their use for inhibiting LINE1 reverse transcriptase, and their use in the treatment of medical disorders, such as cancer, are disclosed herein.
4.WO/2025/255411METHODS AND COMPOSITIONS FOR REDUCING DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
WO - 11.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/032557 Applicant IONIS PHARMACEUTICALS, INC. Inventor BHANOT, Sanjay
Provided herein are methods of treating, preventing, or ameliorating a liver disease comprising administering a composition comprising about 75 mg to about 175 mg of an oligomeric compound comprising a modified antisense oligonucleotide inhibitor of diacylglycerol acyltransferase 2 (DGAT2). Additionally provided are unit doses and dosing regimens useful in the methods for treating, preventing, or ameliorating a liver disease, including MASLD and MASH, and complications thereof.
5.WO/2025/254592A METHOD OF QUANTIFYING NUCLEIC ACIDS
WO - 11.12.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/SG2025/050383 Applicant MIRXES LAB PTE. LTD. Inventor YEOH, Khay Guan
There is provided a method of quantifying and/or identifying one or more nucleic acids associated with a condition. In one embodiment, the method identifies unannotated transfer RNA-derived fragments (tRFs). In one embodiment, the method identifies boundaries where nucleic acid sequence read ends are frequently detected, using a statistical model, such as Hidden Markov Model. There is also provided a method of determining / predicting a condition of a subject. In one embodiment, the method comprises using a scoring pipeline, such as tScore pipeline, that compares two sample groups, such as a cancer group and a healthy group, to assign quantitative scores to individual sequencing reads that extend to each sample. Also disclosed is a method of determining whether a subject suffers from or is at risk of developing a condition, such as cancer.
6.WO/2025/255402CRYSTALLIZATION OF SIAMENOSIDE I
WO - 11.12.2025
Int.Class C07H 15/207
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
20Carbocyclic rings
207Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
 Appl.No PCT/US2025/032542 Applicant THE COCA-COLA COMPANY Inventor MERCOGLIANO, Christopher
Crystal forms, compositions, and methods related to Siamenoside I are provided. An example crystal form of Siamenoside I has an orthorhombic crystal system with a space group of P212121. The crystal form of Siamenoside I is further characterized by an X-ray powder diffraction pattern including diffraction peaks at angles (2θ) of 16.48°±0.2°, 14.39°±0.2°, 15.83±0.2°, and 13.01±0.2°. An example method of making a solid of Siamenoside I includes providing/obtaining a crude solution of Siamenoside I, causing crystallization of Siamenoside I from the crude solution to obtain crystals of Siamenoside I as a precipitate, and isolating the crystals of Siamenoside I from the crude solution. An example method of making a composition containing Siamenoside I includes providing/obtaining a solid of Siamenoside I having the crystal form according to the present disclosure, and dispersing or dissolving the solid of Siamenoside I in a medium.
7.WO/2025/255027LIPID NANOPARTICLES FOR TOPICAL DELIVERY
WO - 11.12.2025
Int.Class C12N 15/88
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
88using microencapsulation, e.g. using liposome vesicle
 Appl.No PCT/US2025/031927 Applicant FLAGSHIP LABS 114, INC. Inventor HU, Qi-Ying
The instant disclosure relates to lipid particles that harbor cationic lipids, the particles found to be capable of delivering associated cargoes - particularly nucleic acid cargoes when formulated as nucleic acid-lipid particles - intracellularly to skin tissue cells when administered topically to a subject. The instant disclosure provides compositions comprising such lipid particles, optionally in association with a therapeutic agent (e.g., a therapeutic mRNA and/or nucleic acid controller system), as well as methods and kits for delivering a lipid particle-associated therapeutic agent and/or for treating or preventing a disease or disorder, e.g., a skin disease or disorder, in a subject, using one or more lipid particle compositions provided herein.
8.WO/2025/254544METHOD FOR OBTAINING PARTRICIN A OR B AND PARTRICIN A AND B OBTAINED BY METHOD
WO - 11.12.2025
Int.Class B01D 15/18
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
DSEPARATION
15Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
08Selective adsorption, e.g. chromatography
10characterised by constructional or operational features
18relating to flow patterns
 Appl.No PCT/PL2025/000009 Applicant POLITECHNIKA GDANSKA (GDANSK UNIVERSITY OF TECHNOLOGY) Inventor GORSKA, Justyna
The invention refers to method for manufacturing pure antibiotics from the group of aromatic polyenemacrotides with potentially high therapeutic index — partricin A and partricin B from a commercial preparation - particin complex- substrate comprising partricin complex among other substances, compositions or from an extract from the fermentation broth of a strain producing partricin A and B - that comprises particin complex, through their isolation. The invention also covers products obtainable by this method.
9.WO/2025/252699BACTERIAL ANTI-ADHESION COMPOUND AND USE THEREOF
WO - 11.12.2025
Int.Class A61P 31/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
 Appl.No PCT/EP2025/065273 Applicant ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) Inventor PERSAT, Alexandre
The invention relates to a compound and use thereof for preventing and/or inhibiting bacterial adhesion to a non-living substrate or a living surface as well as for preventing and/or treating bacterial infection.
10.WO/2025/255054METHODS AND COMPOSITIONS FOR OLIGONUCLEOTIDE BIOCONJUGATION
WO - 11.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/031983 Applicant DARBIX LLC Inventor DHANJEE, Heemal Hansraj
The present disclosure relates to oligonucleotide bioconjugates for targeted therapy, and processes to make the same. The present disclosure also relates to mRNA bioconjugates and pharmaceutical formulations thereof which prevent, slow the progression, or reduce the severity of cancer. Additionally, the present disclosure relates to mRNA bioconjugates and pharmaceutical formulations thereof which prevent, slow the progression, or reduce the severity of obesity or one or more other metabolic and/or cardiovascular disorders.
# -